BIIB - Biogen Inc.
Bank of Nova Scotia purchased a new stake in Biogen Inc. (NASDAQ: BIIB) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,446 shares of the biotechnology company's stock, valued at approximately $3,553,000. Several other institutional investors and hedge
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 /PRNewswire/ -- Eisai Co., Ltd.
Allworth Financial LP acquired a new stake in Biogen Inc. (NASDAQ: BIIB) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,033 shares of the biotechnology company's stock, valued at approximately $1,736,000. A number of other hedge funds have also added
Shares of Biogen Inc. (NASDAQ: BIIB - Get Free Report) have received an average recommendation of "Moderate Buy" from the thirty-three research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, eighteen have assigned a buy recommendation
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
BlackRock Inc. bought a new stake in Biogen Inc. (NASDAQ: BIIB) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 15,985,736 shares of the biotechnology company's stock, valued at approximately $3,453,878,000. BlackRock Inc. owned approximately 10.82% of Biogen as of its
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology.
Amundi increased its stake in Biogen Inc. (NASDAQ: BIIB) by 38.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 790,827 shares of the biotechnology company's stock after buying an additional 218,398 shares during the period. Amundi owned about 0.54%
It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut in adjusted net income guidance.
Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96.
Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon's Fed decision on interest rates.
Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
A quarter-points rate hike has been bandied about as a possibility today.
Biogen Inc. is upgraded to 'Buy' as strategic acquisitions and pipeline progress offset multiple sclerosis portfolio erosion. Q2 revenue grew 3% Y/Y, aided by Apellis acquisition, rare disease, and Alzheimer's collaboration, with LEQEMBI gaining global traction. Felzartamab's multi-indication potential and upcoming pivotal trial readouts underpin BIIB's long-term growth prospects.
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen NASDAQ: BIIB reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company's growth portfolio generated more than $1 billion in quarterly revenue, up 24% from the prior-year period.
Biogen Inc. (BIIB) came out with quarterly earnings of $3.6 per share, beating the Zacks Consensus Estimate of $3.04 per share. This compares to earnings of $5.47 per share a year ago.
Biogen Inc (BIIB) released its 8-K filing on July 29, 2026, indicating notable performance in its recent quarter amid ongoing challenges in its legacy business.